NOTICE OF LIMITED COMPETITION FOR COMPETING SUPPLEMENTAL APPLICATIONS TO
DISSEMINATE PROMISING CANCER CONTROL INTERVENTIONS TESTED IN EFFECTIVE
RESEARCH PROJECTS
Release Date: May 9, 2001
NOTICE: NOT-CA-01-010
National Cancer Institute
The National Cancer Institute’s (NCI) Division of Cancer Control and
Population Sciences (DCCPS) announces a limited competition for competing
supplemental applications to NCI-funded research projects supported by R01,
P01, P50, U01 and U19 grant mechanisms. Most researchers who propose to
develop and test cancer control interventions either explicitly or implicitly
intend to disseminate the interventions within the populations from which the
sample is drawn if the interventions prove efficacious. However, without
financial support for the costs of dissemination, active dissemination rarely
occurs. The purpose of these supplements is to fund the dissemination of
promising interventions where statistical significance and potential public
health/clinical significance of intervention effects strongly suggest the
merits of dissemination to the broader population from which the intervention
sample was drawn. The supplement may also support cost-effectiveness
evaluations of interventions, qualitative and quantitative research needed to
adapt intervention products for use after formal research evaluation has ended
and dissemination of intervention products.
These supplements have been designed to provide one-year funding (with the
possibility of a second year of supplemental funding) to cancer control
investigators whose intervention efficacy data have been analyzed, who are in
the final years of their R01, P01, P50, U01 or U19 awards. Research results
should show statistical significance and public health/clinical significance
of intervention effects and thus provide the rationale for dissemination to
the broader population from which the intervention sample was originally
drawn. Intervention research across the cancer control continuum, that may
be eligible for these supplements, includes: tobacco use prevention and
cessation, promotion of appropriate changes in diet and physical activity,
reduction of sun exposure and UV radiation exposure, facilitating informed
decisions about genetic testing for cancer susceptibility, enhancing screening
for breast, cervix and colorectal cancers, and improving coping skills and
quality of life for cancer survivors and their families.
Requests for competing supplements under this program should be developed
using standard forms and format of the PHS 398 (revised 4/98). All sections
of the PHS 398 package should be completed. Also include the following with
the PHS 398:
A. Cover letter requesting the competing supplement and identifying this
program
B. Face page
C. Budget and budget justification
D. Biosketches and other support for participating investigators
E. Description of the proposed dissemination plan, including an introduction,
intervention efficacy data justifying dissemination, relevance to target
populations and settings for dissemination, proposed dissemination theory and
methodology, procedures to assess dissemination program effectiveness, and
plans to sustain effective dissemination approaches beyond the supplement
funding period (not to exceed 12 pages),
F. Intervention products (or copies) should be provided
G. Relevant letters of support from key partners should be included.
Requests should contain enough detail to allow assessment of the scientific
merit of the proposed dissemination plans and the appropriateness of the
request for supplemental funding. Budgets may not exceed $100,000 in direct
costs for a time period not exceeding 12 months. If there are extenuating
circumstances that require a larger budget, these should be documented and
justified. If this initiative is reissued, a second one-year administrative
supplement may be requested to complete the dissemination work initiated in
the first supplement year. Funding of the subsequent administrative
supplement will depend on an administrative review of the first year’s
progress report and availability of funds. All requests require an itemized
budget and must be countersigned by the grantee institution’s business office.
Requests for supplements under this program must comply with NIH policies for
inclusion of women, minorities, and children in research involving human
subjects.
Submissions may be made to this supplement no earlier than 24 months and no
later than six months prior to the end of the last year of a currently funded
NCI intervention research R01, P01, P50, U01 or U19 and no later than August
16, 2001. Investigators planning the submission of a competing continuation
application (Type 2) of their R01, P01, P50, U01 or U19 intervention research
award may submit the supplement application after, and if, the award notice of
the Type 2 application has been made, and if the Type 2 application does not
include funding for the dissemination effort. In this case, the supplement
(if awarded) will be linked to the Type 2 award to disseminate the evidence-
based intervention tested in the original R01, P01, P50, U01 or U19 (Type 1)
project.
Requests will undergo review for scientific merit by extramural reviewers with
expertise in the cancer control intervention area and/or in dissemination and
diffusion research. Awards will be determined on the basis of scientific
merit, program relevance, dissemination potential, and availability of funds.
Special consideration will be given to applications that plan to disseminate
interventions tested in low income and ethnically diverse populations.
The earliest anticipated award date for this program will be March 1, 2002.
Inquiries related to this notice should be addressed to the NCI Program
Director for the particular R01, P01, P50, U01 or U19 for which the supplement
is being requested. Applicants are STRONGLY ENCOURAGED to discuss the
efficacy data (e.g. effect sizes, consistency with prior research, relevance
to target populations) supporting their competing supplement request from the
original project with their respective NCI research project Program Director
prior to submission.
INQUIRIES
Requests should be sent to:
Jon F. Kerner, Ph.D.
Assistant Deputy Director for Research Dissemination and Diffusion
Division of Cancer Control and Populations Sciences
6130 Executive Boulevard
Executive Plaza North, Room 6144
Rockville, MD 20852
Direct inquiries regarding fiscal matters should be made to:
Ms. Crystal Wolfrey
Grants Administration Branch
6120 Executive Boulevard
Executive Plaza South, Room 243
Rockville, MD 20852
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|